Status:
COMPLETED
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Sanofi
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second line therapy in patients with stage IV, metastatic breast cancer
Detailed Description
Eligible patients will receive a minimum of six cycles of combination therapy. If a patient is still responding to the oxaliplatin at 6 cycles, the oxaliplatin may be continued with the trastuzumab up...
Eligibility Criteria
Inclusion
- Females ≥ 18 years of age
- Histologically confirmed breast cancer that is HER2/neu positive (3+ by IHC or FISH +) and evidence of metastatic disease. Tumor may be of any estrogen and progesterone receptor type
- Measurable disease by RECIST and an ECOG ≤ 2
- Patients with known evidence of brain metastases are eligible if they are asymptomatic and have completed all therapy (surgery, radiotherapy, and/or steroids)
- Baseline LVEF value within the institutional normal range
- Any number of prior hormonal therapy treatments in the adjuvant setting or for metastatic disease. A subject must have progressed on hormonal therapy and all hormonal therapy (including birth control pills) must be discontinued at study entry.
- Prior chemotherapy in the adjuvant setting and up to one prior chemotherapy regimen for metastatic disease is allowed.
- Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab.
- Prior radiation therapy in the adjuvant setting or for metastatic disease, provided it was not to the only site of evaluable disease.
- All prior chemotherapy, trastuzumab and radiation therapy should be completed \> 2 weeks before enrollment.
- Patients receiving bisphosphonate therapy are eligible. However, if bisphosphonate were started within \< 2 months prior to enrollment, the bone lesions will not be evaluated for response and the patient must have another site of metastatic disease that is either measurable or evaluable for response.
- Patients must have recovered from toxicities due to prior therapy.
- Lab values in accordance with the protocol
- Patients must be nonpregnant and nonlactating. Patients of childbearing potential must implement an effective method of contraception during the study (birth control pills are not allowed).
Exclusion
- Bone only disease are ineligible
- Patients who received more than 1 prior chemotherapy regimen for metastatic disease are ineligible.
- Patients with a history of other cancers except curatively-treated carcinoma of the cervix in situ or non-melanomatous skin cancer.
- Active serious infection or other underlying medical condition that would impair their ability to receive protocol treatment.
- Uncontrolled nervous system metastases
- Dementia or significantly altered mental status that would interfere with proper consenting.
- Receiving other investigational therapy.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00297596
Start Date
February 1 2006
End Date
October 1 2010
Last Update
October 28 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Graves-Gilbert Clinic
Bowling Green, Kentucky, United States, 42101
2
Hematology Oncology Life Center
Alexandria, Louisiana, United States, 71301
3
Baton Rouge General Medical Center
Baton Rouge, Louisiana, United States, 70806
4
Oncology Hematology Care
Cincinnati, Ohio, United States, 45242